115 related articles for article (PubMed ID: 16857819)
1. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
[TBL] [Abstract][Full Text] [Related]
2. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
4. EGFR FISH versus mutation: different tests, different end-points.
Cappuzzo F
Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
[TBL] [Abstract][Full Text] [Related]
5. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
Eberhard DA; Giaccone G; Johnson BE;
J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
[TBL] [Abstract][Full Text] [Related]
7. EGFR inhibitors: what have we learned from the treatment of lung cancer?
Giaccone G; Rodriguez JA
Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization.
Gallegos Ruiz MI; Floor K; Vos W; Grünberg K; Meijer GA; Rodriguez JA; Giaccone G
Histopathology; 2007 Nov; 51(5):631-7. PubMed ID: 17927584
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
10. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
12. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Amler LC; Goddard AD; Hillan KJ
Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
[TBL] [Abstract][Full Text] [Related]
14. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Uramoto H; Mitsudomi T
Br J Cancer; 2007 Mar; 96(6):857-63. PubMed ID: 17325698
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Hirsch FR; Varella-Garcia M; Cappuzzo F
Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
[TBL] [Abstract][Full Text] [Related]
16. EGFR assays in lung cancer.
Dacic S
Adv Anat Pathol; 2008 Jul; 15(4):241-7. PubMed ID: 18580100
[TBL] [Abstract][Full Text] [Related]
17. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
da Cunha Santos G; Saieg MA; Geddie W; Leighl N
Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression.
Coulibaly B; Nanni I; Quilichini B; Gaudart J; Metellus P; Fina F; Boucard C; Chinot O; Ouafik L; Figarella-Branger D
Hum Pathol; 2010 Jun; 41(6):815-23. PubMed ID: 20303140
[TBL] [Abstract][Full Text] [Related]
19. Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?
Belani CP; Ramalingam S
Clin Lung Cancer; 2005 Jul; 7(1):8. PubMed ID: 16098237
[No Abstract] [Full Text] [Related]
20. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.
Hirsch FR; Dziadziuszko R; Varella-Garcia M; Franklin WA; Gandara DR; Bunn PA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S138-42. PubMed ID: 18520298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]